We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Faron Pharmaceuticals Oy | LSE:FARN | London | Ordinary Share | FI4000153309 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.42% | 117.50 | 115.00 | 120.00 | 117.50 | 117.50 | 117.50 | 4,573 | 08:00:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -28.73M | -0.4177 | -2.81 | 80.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/7/2020 08:54 | Signs of life! | raldo | |
22/6/2020 11:20 | This is a good reading:https://link | yep1234 | |
22/6/2020 11:08 | Not for severe Ards patients | cwebb07 | |
22/6/2020 11:07 | Toffeeman, in COVID-19 patient’s lungs are filled with liquid. It is hard to inhale anything to your bloodstream. Maybe something will go through and help the patient, but a lot of it will stay out. All IMO of course. | yep1234 | |
22/6/2020 10:42 | Or SNG001 which will be administered pre-ICU! | toffeeman | |
22/6/2020 09:45 | Toffeeman...Interfer | cwebb07 | |
22/6/2020 09:43 | Immunomodulation is complex, and timing of the treatments is critical. There are a limited number of direct studies on the timing of immunomodulatory treatments such as IFN-beta, but given our basic understanding of human biology and viral defence, we suggest that IFN-beta should be given early to COVID-19 patients. In mild cases such as in the recent clinical trial, even s.c. administered IFN-beta was effective [1], but in more severe cases, i.v. injections are needed to rapidly reach the endothelium. As ARDS rises together with a cytokine storm, corticosteroids may play a beneficial role during the later fibrotic phase or just by calming down the cytokine storm after IFNs have had their impact. This is supported by Villar et al. who showed that the use of dexamethasone was associated with better survival in ARDS [12]. A notable feature of this study is that the enrolled patients were not on steroids when entering the trial | cwebb07 | |
22/6/2020 09:16 | That article references that.It's about when Traumakine is issued and how severe the patient is.They both have a benefit in covid..the difference being Traumakine will have an ongoing benefit with patients with ARDS not linked to Covid | cwebb07 | |
22/6/2020 08:23 | https://ccforum.biom | cwebb07 | |
20/6/2020 17:09 | Maybe this link works instead:https://acad | yep1234 | |
20/6/2020 17:08 | Good reading from Oxford University press for the infectious Diseases Society of America regarding Interferon beta 1a (as is Traumakine, just i.v version of it) in SARS-Cov-2:https://w | yep1234 | |
19/6/2020 18:40 | Slight concern that steroids are now being recommended to treat Covid 19 and yet the Trakumine trial is for patients excluding from using steroids. it will be an interesting outcome. | zipstuck | |
15/6/2020 09:59 | Think you'll find they don't just thrown money away at any company. Underpins the funding as we move forward | bwgs | |
15/6/2020 09:24 | You have to wonder what prompted this. Feedback from Traumakine users? Opportunitism. Take the loan because it is available now? A current example of the benefits of having a having a specialised manufacturing capability is OXB. | hashertu | |
15/6/2020 08:39 | Have to believe one day we will open up at £10+ | cwebb07 | |
13/6/2020 08:10 | Faron's scientific network at work for COVID-19: https://ccforum.biom | yep1234 | |
19/5/2020 16:20 | Now that would be interesting for us | bwgs | |
19/5/2020 11:48 | According to Faron's RNS regarding grant from Business Finland as part of Cancer IO on 11.5.2020:- Clevegen to be studied in experimental combinations with anti-cancer molecules from other consortium membershttps://cance | yep1234 | |
11/5/2020 17:29 | https://cancerio.org | yep1234 | |
05/5/2020 12:57 | Trust this was the replacement for the company that pulled out last year ? | bwgs | |
05/5/2020 09:49 | I think that news had been discounted already | toffeeman |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions